Oncology's Green Light Podcast · OncologyResearch · FDA Approvals: AI-Powered Insights for everyday oncology clinicians

Learn about the recent FDA approval of nivolumab + ipilimumab for first-line unresectable or metastatic HCC. Stay informed and join the conversation! #HCC #Immunotherapy #FDAapproval #Oncology #Podcast #CheckMate9DW #Nivolumab #Ipilimumab open.spotify.com/show/6yKyfXw...

FDA ☑️ Nivo/Ipi in Unresectable/Metastatic #HCC
☑️OS 23.7M vs. 20.6M vs lenvatinib or sorafenib (HR, 0.79; 95% CI, 0.65-0.96; P = .018).
@FDAOncology @EAHPBA #immunotherapy @bristolmyerssquibb.bsky.social #cancer #CancerResearch #Checkmate9DW